The use of PanDrugs to prioritize anticancer drug treatments in a case of T-ALL based on individual genomic data

Acute T-cell lymphoblastic leukaemia (T-ALL) is an aggressive disorder derived from immature thymocytes. The variability observed in clinical responses on this type of tumours to treatments, the high toxicity ...

Source: BMC Cancer - October 26, 2019 Category: Cancer & Oncology Authors: Pablo Fern ández-Navarro, Pilar López-Nieva, Elena Piñeiro-Yañez, Gonzalo Carreño-Tarragona, Joaquín Martinez-López, Raúl Sánchez Pérez, Ángel Aroca, Fátima Al-Shahrour, María Ángeles Cobos-Fernández and José Fernández-Piqueras Tags: Research article Source Type: research